BioMotiv
Overview
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million US and UK initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs.
Investment Focus
- Innovative therapeutic programs
- Strong scientific evidence
- Experienced management teams
- Potential for significant patient impact
- Alignment with BioMotiv's strategic focus areas
Portfolio Companies
Reach BioMotiv directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about BioMotiv
What sectors does BioMotiv invest in?
BioMotiv invests in Healthcare, Life Sciences, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Cleveland, Ohio, United States. BioMotiv is listed as a corporate vc in the ConnectSafely investor database.
What stage does BioMotiv invest at?
BioMotiv backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 1M - 50M.
Which regions does BioMotiv invest in?
BioMotiv invests across United States.
What companies has BioMotiv invested in?
BioMotiv's portfolio includes SapVax, Inclera, Orca Therapeutics, Koutif Therapeutics, Nynex Therapeutics, Optikira, Sujana and Dual Therapeutics.
How do I contact BioMotiv?
BioMotiv's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database
